Argos Therapeutics to Discuss Automated Manufacturing Process for Personalized Immunotherapy at IBC Next Generation Vaccines Conference

Business Wire, July 14, 2008

DURHAM, N.C. -- Argos Therapeutics today announced that Tamara Monesmith, Director of Manufacturing and Process Development, will present details on the Company's automated approach to manufacturing personalized dendritic cell immunotherapies. The Company's advanced manufacturing process is complementary to its Arcelis[TM] technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. The presentation will take place at the IBC Next Generation Vaccines Conference in National Harbor, MD, on July 17, 2008.

Monesmith's presentation will discuss how Argos' proprietary manufacturing process addresses the challenge of delivering dendritic cell-based therapies that achieve maximum clinical efficacy, as well as the successful commercial production of consistent products. Argos has developed working prototypes of equipment capable of automating cellular and RNA processing. These automated devices carry out autologous immunotherapy production at higher throughput and with a lower cost of goods versus manual processing methods. The automated system includes three standalone units: an RNA processing unit and two cellular processing units (designed to perform the various cellular and plasma processing steps) that use functionally closed disposables. Development advantages for this approach include that it is commercially feasible, involves routine clinical procedures, provides years of therapy with a single production run, and benefits from a clear regulatory path.

Additional details on the IBC Next Generation Vaccines Conference can be found at http://www.ibclifesciences.com/vaccines/overview.xml.> About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off. www.argostherapeutics.com